STOCK TITAN
  1. Home
  2. Sec-filings
  3. EUDA
  4. [6-K] EUDA Health Holdings Ltd Current Report (Foreign Issuer)

EUDA Health (NASDAQ: EUDA) ends Streeterville warrant and updates charter

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

EUDA Health Holdings Limited updated its corporate charter and removed a potential source of new shares. The company adopted an Amended and Restated Memorandum and Articles of Association that, among other changes, expressly allows its board or shareholders to divide or combine ordinary shares by resolution.

EUDA also repurchased for US$125,000 and cancelled a warrant previously issued to Streeterville Capital, LLC that had been immediately exercisable for up to 2,000,000 ordinary shares. The warrant is no longer outstanding, and the potential share issuance under this agreement has been fully eliminated.

Positive

  • None.

Negative

  • None.

Insights

EUDA clarifies charter powers and removes a sizeable warrant overhang.

EUDA Health has formalized flexibility in its share capital by adopting an Amended and Restated Memorandum and Articles that permit directors or members to divide or combine ordinary shares. This gives the company clear authority for future share consolidations or splits under defined resolutions.

The company also repurchased and cancelled a Streeterville Capital warrant for US$125,000. That warrant had been exercisable into up to 2,000,000 newly issued ordinary shares, so its cancellation removes a meaningful block of potential future share issuance tied to this specific financing agreement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did EUDA (EUDA) announce regarding the Streeterville warrant?
EUDA repurchased and cancelled the Streeterville warrant in full. On February 27, 2026, the company bought back the warrant for US$125,000 and then cancelled it, so it is no longer outstanding under the prior securities purchase agreement.

How many shares could the cancelled EUDA (EUDA) warrant have generated?
The cancelled warrant was exercisable for up to 2,000,000 ordinary shares. It had been immediately exercisable into newly issued EUDA ordinary shares, and its cancellation fully removes that potential share issuance from this agreement going forward.

What corporate charter change did EUDA (EUDA) implement in February 2026?
EUDA adopted an Amended and Restated Memorandum and Articles of Association. Filed on February 27, 2026, the updated charter explicitly describes the company’s ability to divide or combine ordinary shares through resolutions of directors or members.

Why is the EUDA (EUDA) warrant repurchase potentially important for shareholders?
The repurchase eliminates a large potential future share issuance. By cancelling a warrant that was exercisable into up to 2,000,000 new ordinary shares, EUDA removed this particular source of possible additional equity tied to the Streeterville Capital financing agreement.

How much did EUDA (EUDA) pay to repurchase the Streeterville warrant?
EUDA paid a total purchase price of US$125,000. The payment was made on February 27, 2026, to repurchase the warrant in full, after which the instrument was cancelled and ceased to exist as an outstanding security.

Is EUDA (EUDA) retaining any warrants under the November 26, 2025 agreement?
No warrants remain outstanding under that agreement. Following the repurchase and cancellation of the Streeterville Capital warrant, the company states that there are no warrants remaining and the related potential share issuance has been fully eliminated.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2026

 

Commission File Number: 001-40678

 

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

 

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: +65 6327 1110

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

 

 

 

 
 

 

On February 27, 2026, EUDA Health Holdings Limited, a company incorporated in the British Virgin Islands (the “Company”), filed an Amended and Restated Memorandum and Articles of Association (the “A&R Charter”) with the BVI Registrar of Corporate Affairs, to, among other things, set out the Company’s ability to divide or combine its ordinary shares, including the ability to effect a share combination by way of resolution of directors or resolution of members. A copy of the A&R Charter is filed as Exhibit 3.1 to this Current Report on Form 6-K and is incorporated herein by reference.

 

On March 4, 2026, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

 

This Report on Form 6-K is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-282723) and the prospectus thereof and any prospectus supplements or amendments thereto.

 

Exhibits

 

3.1   Amended and Restated Memorandum and Articles of Association dated as of February 27, 2026.
99.1   Press release dated March 4, 2026

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: March 5, 2026  
   
EUDA Health Holdings Limited  
   
  /s/ Alfred Lim  
By: Alfred Lim  
  Chief Executive Officer  

 

 

 

 

Exhibit 99.1

 

EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

 

SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC.

 

Background of the Warrant

 

As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and January 13, 2026.

 

Repurchase and Cancellation

 

On February 27, 2026, the Company repurchased the warrant in full for a total purchase price of US$125,000. Following the repurchase, the warrant was cancelled and is no longer outstanding.

 

As a result of this transaction, there are no warrants remaining under this agreement, and the potential issuance of shares associated with the warrant has been fully eliminated.

 

About EUDA Health Holdings Limited

 

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

 

Forward-Looking Statements

 

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Christensen Advisory

 

Christian Arnell
Phone: +852 2117 0861
Email: christian.arnell@christensencomms.com

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

40 documents

Press Releases

Other Documents